65 results about "Related derivatives" patented technology

A multidimensional energy decision system, comprising a plurality of server systems, including at least a statistics server and an interface adapted to receive and send digital information from at least a client system, and further adapted to optionally communicate with the digital exchange via a packet-based data network, wherein the multidimensional energy decision system periodically optimizes operational parameters of client system for a specific time period and a specific energy asset from client system based on forecasted conditions, and directly, or upon decision confirmation from a client system, procures or makes dispatchable energy resources, related externalities, or related derivative financial products, available to a digital exchange or other parties, wherein upon the purchase of a listed asset by another party or across digital exchange, implements dispatch procedures to satisfy the issued contract and, optionally, provides monitoring and verification of performance, is disclosed.

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

Compounds of Formula 1 where Y is a bivalent radical having Formula 2 or Formula 3 where o is an integer from 1 to 4 where the remaining symbols have the meaning described in the specification are selective agonists of RXR retinoid receptors.

A set of linked methods allows accessing derivative products other than traditional futures and options within an adapted electronic futures exchange type market model, rules and legal environment. One embodiment comprises a linkage of such new methods which provides exchange members with access to several new products giving either entirely new or exact OTC ISDA type credit related derivative exposures.

The invention provides a method for screening stereoselective alpha-hydroxy acid dehydrogenase, comprising the following steps: (1) dissolving a sample to be detected containing alpha-hydroxy acid dehydrogenase in a buffer with pH of 6-9, adding an alpha-hydroxy acid chiral monomer as a substrate, and carrying out conversion reaction in water-bath at 20-50 DEG C; and (2) after the conversion reaction, adding the conversion solution in an FeCl3 developer solution to conduct color development reaction for 5-30 min, when the color development reaction finishes, judging the result according to the color appeared in the reaction solution. The method has no need to carry out derivatization on the substrate which is intend to screen, can rapidly identify the dehydrogenase activity and optical selectivity of the selected microbe by using simple colourimetry, has the advantages of simple screening flow, fast speed, low request for devices, strong versatility and the like, and offers great conveniences to the obtainment of optically pure products by using racemic mandelic acid and related derivatives as substrates to carry out resolution through biological enzymatic method.

The present invention provides a novel process for preparing [1-(mercaptomethyl)cyclopropyl]acetic acid with high purity and related derivatives.

Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and / or destruction of nonmalignant proliferating vasculature.

Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and / or destruction of nonmalignant proliferating vasculature.

An automated method and system achieves higher than currently possible leverage in trading synthetic positions (e.g., Asset Packages) consisting of cash equivalent and its derivative. The derivative leg of the Asset Package is used as collateral for the whole package to the extent that it hedges the market risk of the synthetic position. The Asset Package Market Maker assembles (quotes) synthetic positions based on the underlying markets' quotes, which includes a discount (embedded margin). The amount of the discount is based on the value of package collateral, such as the put strike in case of a synthetic call position. The discounted synthetic position is then traded in the virtual asset package market, established and made by such a market maker on a real-time basis. The method and system are applicable to various assets and related derivatives. The method and system herein can be used for trading any asset, right or liability not just securities, equities, derivatives or other like instruments.

The present invention is directed to a method of treating a subject for a pulmonary disease by administering a therapeutically effective amount of a compound of the formula:wherein R1, R2 or R3 are each independently a C1 to C6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R1, R2 or R3 each independently is a C1 to C6 alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and / or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification and an inhalable carrier, as well as the above modified compound.

A derivative financial instrument is created which facilitates the reallocation of a risk caused by the occurrence of an event or condition. For example, a system, method, and media are directed to allocating risks of water shortages. A computer-readable financial instrument is established based on a water availability score that is calculated from one or more types of hydrological factors, a settlement value function, and a settlement date. The financial instrument is configured to transfer, on the settlement date, a cash or physical commodity amount to a buyer or seller of the instrument as determined by the contract specification if the score is zero, or a positive or negative number or within a specified range of positive or negative values.

The invention discloses a method and device for preparing and purifying a carbon dioxide adsorbent used for removing carbon dioxide from airflow and belongs to the technical fields of air pollution control and environmental protection. The method is characterized by comprising the following steps: mixing salts of iron or manganese or cobalt or copper and related derivative materials, alkali or alkaline substances and related derivative materials, water and a forming agent according to a certain ratio and procedure, drying and activating the obtained solid compound or mixture so as to obtain asolid product, namely the adsorbent. The adsorbent is introduced into a gas-solid reactor, the carbon dioxide in the airflow carries out a gas-solid reaction with the adsorbent at a certain temperature so as to be removed, and then the adsorbent is regenerated and recycled. The invention furthermore discloses a related purification device.

The invention discloses a cinchona alkaloids compound with a new macrocyclic structure, and a preparation method thereof. The cinchona alkaloids compound is prepared with cinchona alkaloids quinidine as a substrate. According to the preparation method, quinidine is subjected to a halogen cyclization reaction, such that the new macrocyclic structure is obtained. Related derivatives can be obtained through the changes on the C11-locus. The cinchona alkaloids compound provided by the invention can be used as a novel chiral catalyst or a ligand. The preparation method is simple, and yield is high.

The invention provides an application of Retro-2cycl and / or Retro-2.1 and related derivatives in preparing drugs for preventing and / or treating diseases induced by small RNA virus infection. Researches in the invention verify that the Retro-2cycl and / or Retro-2.1 and the related derivatives can effectively inhibit cytopathic effect and viral plaque effect induced by an enterovirus 71, remarkably reduce the output of progeny viruses of the enterovirus 71 and remarkably inhibit an enterovirus 71 infected mouse. The researches prove that Retro-2cycl and / or Retro-2.1 and related derivatives can effectively prevent and / or treat diseases induced by small RNA virus infection.

The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and / or ASH.

The present invention provides a scalable synthesis of enantiomerically pure brivaracetam, and related derivatives.

The present invention relates to the field of organic synthesis and describes the synthesis of specific triazolopyrimidine compounds and intermediates thereof as well as related derivatives, suitable for the preparation of Ticagrelor (TCG).

Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin assembly. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and / or destruction of nonmalignant proliferating vasculature.

The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and / or ASH.

The invention belongs to the technical field of fluorescent molecular dye preparing and purifying and relates to highlight and high-purity water solubility fluorescent molecules and a preparing method thereof, in particular to highlight and high-purity water solubility fluorescent molecules which are prepared through citric acid, ethylenediamine, related derivatives of ethylenediamine or analogues of ethylenediamine through a hydrothermal method and subjected to column chromatography or extraction purification and the preparing method. Compared with marketed fluorochrome, the highlight and high-purity water solubility fluorescent molecules are low in price and have bright and stable blue fluorescence, good fluorescent stability, low biotoxicity and the like, laboratory preparation IPCA synthesis is easy and convenient, and modifying and coupling are facilitated due to the fact that active groups (carboxyl) are contained. The highlight and high-purity water solubility fluorescent molecules have potential application in the field of bioimaging, fluorescence labeling, fluorescence printing and the like.

The present invention is directed to processes for the preparation of lisdexamfetamine and related derivatives, wherein the processes comprise coupling to racemic or enantiomerically enriched amphetamine and wherein the resulting product is advantageously enantiomerically or diastereomerically enriched in the desired stereoisomer.

The invention discloses a cold-processed seabuckthorn handmade soap for sun protection and repairing and a preparation method thereof, which is characterized in that the components include olive oil, coconut oil, palm oil, shea butter, castor oil, milk, cocoa butter or beeswax, seabuckthorn or Its derivatives (sea buckthorn oil, sea buckthorn powder, sea buckthorn tea, sea buckthorn wine or sea buckthorn enzyme and related derivatives, etc.), purified water, NaOH, HHBP, natural flavors. Seabuckthorn and its derivatives are put into soap, which has the functions of repairing sun damaged, sensitive skin and mucous membranes, promoting cell and skin growth, blocking free radicals produced by peroxidation to achieve anti-aging, and improving skin resistance. The present invention adds the seabuckthorn and its derivatives to the handmade soap by low-temperature cold processing, retains the nutritional components of each seabuckthorn derivative, and can fully exert its functions and effects. Seabuckthorn and its derivatives have become a new functional additive for handmade soaps and have very broad application prospects.

The invention provides a novel strain of (S) producing-mandelic acid dehydrogenase, that is, Pseudomonas aeruginosa ZJB1125, which is preserved in the China Center for Type Culture Collection with the preservation number CCTCC No:M 2011394 on 13 November 2011 in Wuhan University, Wuhan, China, 430072. (R)-mandelic acid and related derivatives with high optical purity prepared by the strain of the invention have the high optical purity of more than 99 %, and both the yield and corresponding oxidation product ketonic acid yield of being close to 50 %. By using the strain of the invention to split alpha-hydroxy acid raceme, the advantages of simple and safe operation, low cost, mind reaction conditions and the like are achieved, more importantly, the atom economy of the process is significantly raised, and the invention has good industrial application prospects.

Embodiments in accordance with the present invention relate to the fabrication of thin (>1 μm) polycrystalline, nanocrystalline, or amorphous silicon films on a substrate. Particular embodiments utilize liquid sources of silane, including but not limited to cyclohexasilane (CHS), cyclopentasilane (CPS) or related derivatives of these compounds. In one embodiment, the silane is applied in liquid form contained by the use of a series of raised walls. Subsequent polymerization results in the material being a solid form. In other embodiments, the silane is applied as a liquid which is then frozen, with subsequent localized melting allowing polymerization to convert the material into a stable solid form. Embodiments of the present invention are particularly suited for forming thick (>10 μm) silicon films needed to achieve light absorption efficiencies deemed acceptable for thin film photovoltaic devices.

The invention relates to an integrated comprehensive service platform of a scenic area. The platform comprises a storage database system, a cloud platform operation system, a terminal portal system, an application management system and a derivative service system, wherein both the cloud platform operation system and the application management system are connected with the storage database system and the derivative service system, the storage database system is connected with the derivative service system, the cloud platform operation system is connected with the application management system,and the terminal portal system is connected with the cloud platform operation system. The corresponding response is performed according to the request of the object to be managed, the service and management are provided for the object to be managed, the information of the scenic area is collected and the related derivative services are extended based on business resources, and the comprehensive one-stop service can be provided for service staffs facing the object to be managed.

Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

The invention relates to the technical field of locksets, in particular to a manual / automatic key cylinder structure and a manual / automatic suitcase lock and a safe suitcase, wherein the key cylinderstructure comprises a key cylinder cavity housing, a translation lock shaft, a drive motor and a key locking head; a perpendicular key hole is formed in the key cylinder cavity housing; the translation lock shaft is provided with a first limiting lock plate and a second limiting lock plate and is assembled in the key cylinder cavity housing; an eccentric guide wheel matched with the first limitinglock plate is mounted on the drive motor; and an eccentric balance wheel matched with the second limiting lock plate is mounted on the key locking head. According to the invention, the translation lock shaft and the drive motor are cooperated to realize the automatic locking or unlocking function of the key cylinder; and the translation lock shaft and the key locking head are cooperated to realize the manual locking or unlocking function of the key cylinder, so that the using diversity and using safety of the key cylinder, the lockset and related derivative products are greatly ensured.

Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

The present invention relates to methods for the synthesis of galanthamine, morphine, intermediates, salts and derivatives thereof. In preferred embodiments, the invention relates to methods for improving the efficiency and overall yield of said morphine, morphine related derivatives and intermediates thereof. In further embodiments, the invention relates to methods for improving the efficiency and overall yield of galanthamine and intermediates thereof.

This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.